{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.18","upperLimit":"46.23","value":"38.51"},{"groupId":"OG001","lowerLimit":"42.18","upperLimit":"62.32","value":"49.58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"251"}],"units":"Participants"}],"description":"Overall Survival was measured from the date of randomization to the date of the participant's death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bortezomib 1.3 milligrams per square meter (mg/m\\^2) subcutaneous (SC) injection on Days 1, 4, 8, and 11 of each 21-day cycle (8 treatment cycles) and dexamethasone 20 milligrams (mg) orally (PO) on Days 1, 2, 4, 5, 8, 9, 11, and 12 of the first 8 bortezomib treatment cycles. Participants who met sponsor-confirmed disease progression eligibility criteria received daratumumab monotherapy as a subsequent antimyeloma therapy as follow: daratumumab 16 milligrams per kilogram (mg/kg) intravenous (IV) infusion or daratumumab SC injection (1800 mg fixed dose) weekly for the first 2 cycles, every 2 weeks from Cycle 3 to 6, and then every 4 weeks thereafter.","id":"OG000","title":"Bortezomib + Dexamethasone (Vd)"},{"description":"Participants received daratumumab 16 mg/kg IV infusion weekly or daratumumab SC injection (1800 mg fixed dose) for the first 3 cycles, on Day 1 of Cycles 4-8, and then every 4 weeks thereafter, bortezomib 1.3 mg/m\\^2 SC injection administration on Days 1, 4, 8, and 11 of each 21-day cycle (8 treatment cycles) and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 of the first 8 bortezomib treatment cycles.","id":"OG001","title":"Daratumumab + Bortezomib and Dexamethasone (DVd)"}],"paramType":"MEDIAN","populationDescription":"The intent-to-treat (ITT) population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to 6 years 9 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}